pfizer HQ

Pfizer has signed an agreement to acquire quadrivalent meningitis ACWY vaccines Nimenrix and Mencevax from GlaxoSmithKline (GSK) for around $130m (€115m).

Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine) is a single-dose meningococcal ACWY-TT (tetanus toxoid) conjugated vaccine that has been developed to provide protection against Neisseria meningitidis.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Neisseria meningitidis is an uncommon but highly contagious disease that may result in disability and death. Nimenrix is indicated for all age groups above one year of age.

Nimenrix has been approved for sale in 61 countries across the European Economic Area (EEA 30), Canada, Australia and emerging markets.

It is under review with registrations in additional 18 countries across Africa, Asia, Eastern Europe, and the Middle East.

See Also:

"Adding these two innovative and complementary vaccines to our current portfolio will allow us to more completely respond to meningococcal disease outbreaks."

Pfizer Vaccines president Susan Silbermann said: "The addition of Nimenrix and Mencevax is an important milestone for Pfizer Vaccines.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Adding these two innovative and complementary vaccines to our current portfolio will allow us to more completely respond to meningococcal disease outbreaks, as well as proactively address a critical public health need, the prevention of meningococcal disease across all ages."

Mencevax (meningococcal polysaccharide serogroups A, C, Y and W-135 vaccine) is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine designed to control outbreaks of meningococcal infection and for travellers to countries where the disease is endemic or highly epidemic.

It can be used across all age groups from two years of age and currently approved in 79 countries across Africa, Asia, Australia, Europe, Latin America, Middle East and New Zealand.

In 2014, Pfizer received US approval for Trumenbam (Meningococcal Group B Vaccine) to provide protection against serogroup B meningococcal disease in individuals aged ten to 25 years and also acquired Baxter’s NeisVac-C to offer protection against serogroup C meningococcal disease.

Image: Pfizer world headquarters. Photo: courtesy of Jim.henderson.